Researchers find leukemia and lymphoma drug may benefit glioblastoma patients

Researchers find leukemia and lymphoma drug may benefit glioblastoma patients - Hallo friendsLET'S HEALTHY LIFE, In the article you read this time with the title Researchers find leukemia and lymphoma drug may benefit glioblastoma patients, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cough, Article diabetes, Article diseases, Article in general, Article Phytotherapy, Article skin diseases, We write this you can understand. Alright, good read.

Title : Researchers find leukemia and lymphoma drug may benefit glioblastoma patients
link : Researchers find leukemia and lymphoma drug may benefit glioblastoma patients

Read too


Researchers find leukemia and lymphoma drug may benefit glioblastoma patients

In continuation of my update on ibrutinib

New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug for lymphoma and leukemia, may also help treat the most common—and deadliest—type of brain tumor. The findings, published in Science Translational Medicine, offer hope that the drug may one day be used in patients with glioblastoma and improve poor survival rates.


Ibrutinib.png
The team of researchers, led by Shideng Bao, Ph.D., of Cleveland Clinic's Lerner Research Institute found that ibrutinib slowed brain tumor growth in a preclinical model and extended survival more than 10-times the rate of the current standard-of-care chemotherapy drug.
They found in human glioblastoma  that ibrutinib works by inhibiting glioma stem cells—an aggressive type of brain cancer cell that tends to resist treatment and spread. Furthermore, they showed that combining ibrutinib with radiation therapy prevents glioblastoma cells from developing this resistance. Combination therapy overcame resistance and extended lifespan more effectively than either radiation or ibrutinib treatment alone.
According to the American Brain Tumor Association, glioblastoma survival is very poor—median survival in patients undergoing standard treatment is less than 15 months.
"Glioblastoma is the most lethal primary brain tumor and is highly resistant to current therapies," said Bao. "There is an urgent need to get new treatments to these patients as quickly as possible."
In earlier studies, Bao and colleagues found that glioma stem cells have high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transducer and activator of transcription 3), which is responsible for the aggressive, pro-cancer qualities of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting both proteins.
"Additional research is important to understand the effects of ibrutinib in patients, but these early findings are promising," said Bao. "Using an FDA-approved drug would allow us to surpass many of the lengthy regulatory studies needed when developing a new treatment, and we could potentially begin clinical trials very soon."
Ibrutinib (Imbruvica) has been approved by the U.S. Food & Drug Administration to treat certain types of leukemia and lymphoma, as well as chronic graft versus host disease.






Thus Article Researchers find leukemia and lymphoma drug may benefit glioblastoma patients

That's an article Researchers find leukemia and lymphoma drug may benefit glioblastoma patients This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Researchers find leukemia and lymphoma drug may benefit glioblastoma patients with the link address https://letslifes.blogspot.com/2018/08/researchers-find-leukemia-and-lymphoma.html

Subscribe to receive free email updates:

Related Posts :

0 Response to "Researchers find leukemia and lymphoma drug may benefit glioblastoma patients"

Post a Comment